Endo International PLC has agreed to a pelvic mesh settlement to resolve “virtually all known” U.S. vaginal mesh lawsuits over its American Medical Systems (AMS) unit’s defective devices. The company announced the pelvic mesh settlement earlier this week. It indicated that it would reserve an additional $775 million to settle remaining U.S. claims. This brings Endo’s total bill for the dangerously defective devices to $2.6 billion to cover transvaginal mesh settlements.
Paul Campanelli, Endo’s President and Chief Executive Officer, indicated that he believed that this should put the U.S. litigation against AMS to rest.
“We believe it is a very important milestone for Endo to have reached agreements to resolve virtually all known U.S. mesh product liability claims,” Campanelli said. “While it remains possible that additional claims will be filed, we believe today’s announcement will assist most mesh claimants to move forward with their lives and will permit Endo to move forward with an even greater focus on executing against our core strategic priorities,” he added.
According to the new agreements, Endo will begin making payment installments in 2017’s fourth quarter. These payments will continue through the fourth quarter of 2019.
The pelvic mesh settlement will cover approximately 22,000 U.S. pelvic mesh lawsuits pending against American Medical Systems. Plaintiffs are claiming horrifying injuries and serious complications from the devices eroding into the vaginal wall. Most of these claims are pending in the federal multidistrict litigation (MDL) in the Southern District of West Virginia.